Zeiss appoint new business development manager for UK
Asia Baginska joins the team to support advances in intraoperative radiation therapy.
As part of its ongoing commitment to driving innovation in intraoperative radiation therapy (IORT) in the UK, Zeiss is pleased to announce the appointment of a dedicated business development manager. Asia Baginska joined the team in April 2021 with a wealth of experience from her background as a trained NHS and IPEM medical physicist. Specialising in radiotherapy physics, Baginska’s main areas of expertise include dosimetry and QA, treatment planning and the commissioning of new equipment and techniques.
Following her move to the commercial industry in 2016, Baginska has previously enjoyed roles working for a distributor of oncology solutions and as a project manager of linac commissioning services. After a detour into the world of clinical trials and IT product management more recently, Baginska says she is very excited about her new challenge as business development manager at Zeiss.
Baginska will be supporting the company’s intraoperative radiation therapy system – Zeiss Intrabeam 600. As a third generation IORT device from Zeiss, the new Intrabeam 600 delivers a single tumouricidal dose to a well-defined target directly after tumour resection, while sparing adjacent organs at risk using low-energy x-ray photons at a high dose rate. Combining surgery and irradiation into one step, this approach ensures local precision during tumour bed sterilisation, for truly personalised treatments.
Benefits of IORT for the patient are vast, with a reduced overall treatment time meaning that most patients can return to their families and daily routine much faster, when compared with external beam radiotherapy. This is supported by a growing body of scientific literature showing the clinical- and cost-effectiveness of IORT for patients with early-stage breast cancer, demonstrating the unique potential of this technology to improve patient outcomes, shorten treatment times, and reduce the burden on hospitals and health systems.
What’s more, Zeiss’ advancement of novel treatment applicators allows to conform radiation dosage to various target volumes, enabling the usage of IORT in not only breast applications, but also brain and spine. This forms part of the overall Zeiss tumour workflow solution, which also features surgical visualisation and in-vivo pathology technology.
With more than 300 devices globally, the Zeiss Intrabeam 600 is supported by a robust and conclusive body of evidence which confirms the clinical value of personalised and patient-centric IORT treatment options. To learn more about the adoption of IORT technology for breast applications specifically, download the ‘Special Report’ featuring a collection of peer-reviewed articles.
For more information on Zeiss Intrabeam 600 please email or visit our website.
This news story has been sponsored by the companies concerned and does not represent the views or opinions of RAD Magazine.